Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 501–600 of 1,000
Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy
Niwińska, A., Pogoda, K., Jagiełło-Gruszfeld, A., & Duchnowska, R. (2022) · Cancers · doi:10.3390/cancers14040965 · Cited by 14
“In this trial, 612 patients with stable brain metastases were included [51].”
BackgroundINHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer
Liu, M., Smith, R. L., Liby, T. A., Chiotti, K., López, C. S., & Korkola, J. E. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01512-4 · Cited by 15
Park, C., Buckley, E. D., Swearingen, A. E. D. V., Giles, W., Herndon, J. E., Kirkpatrick, J. P., Anders, C. K., & Floyd, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854364 · Cited by 13
“Given that HER2driven cancers seem to preferentially metastasize to the brain, and the apparent brain-penetrance of some therapies (32, 33), we focused on the HER2-directed therapies.”
BackgroundSelf-citationPotential Stereoselective Binding of Trans-(±)-Kusunokinin and Cis-(±)-Kusunokinin Isomers to CSF1R
Ayudhya, C. C. N., Graidist, P., & Tipmanee, V. (2022) · Molecules · doi:10.3390/molecules27134194 · Cited by 14
Aapro, M., Cardoso, F., Curigliano, G., Eniu, A. E., Gligorov, J., Harbeck, N., Mueller, A., Pagani, O., Paluch–Shimon, S., Senkus, E., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.07.011 · Cited by 14
“Among TKIs, tucatinib has not been associated with effects on left ventricular ejection fraction (LVEF) [34], while lapatinib and neratinib were reported to decrease LVEF in 2% and 4% of patients, respectively [42].”
BackgroundInfluentialSelf-citationCSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis
cancer, T. C. E. P. O. B., Wang, T., Chen, J., Yang, J., Fu, M., Hua, W., Wang, J., Liu, Y., Wang, B., Yan, M., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-30 · Cited by 13
Zhang, Y., Tan, D., Xie, Y., Wu, L., Wu, S., Tang, Y., Luo, Y., Xiao, X., & Li, X. (2022) · Journal of Oncology · doi:10.1155/2022/1028851 · Cited by 17
Dent, S. F., Moore, H. M., Raval, P., Alder, L., & Guha, A. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.06.002 · Cited by 13
“The HER2CLIMB trial was unique in that it enrolled a significant proportion (48%) of patients with brain metastases, including those previously untreated, treated and stable, and treated with progressive brain metastases.(6) Among patients with brain metastases, PFS was significantly improved with tucatinib vs placebo…”
BackgroundInfluentialWerter, I. M., Remmelzwaal, S., Burchell, G. L., de Gruijl, T. D., Konings, I. R. H. M., van der Vliet, H. J., & van Oordt, C. W. M. D. H. (2022) · Cancers · doi:10.3390/cancers14225612 · Cited by 14
Novel Therapeutic Approaches in Neoplastic Meningitis
Khosla, A. A., Saxena, S., Ozair, A., Venur, V. A., Peereboom, D. M., & Ahluwalia, M. S. (2022) · Cancers · doi:10.3390/cancers15010119 · Cited by 14
“Trials involving trastuzumab, a HER2 inhibitor, have shown good CNS response in metastatic breast cancer with spread to the brain, but separate results with respect to response in NM are unavailable [68].”
ResultLiu, Q., Li, S., Qiu, Y., Zhang, J., Rios, F. J. O., Zou, Z., & Touyz, R. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1002438 · Cited by 14
“Tucatinib Tukysa 2020 Breast cancer (52)”
Molecular basis and clinical application of targeted therapy in oncology
Tilak, T., Patel, A. K., & Kapoor, A. (2023) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2023.02.001 · Cited by 14
Modern Management and Diagnostics in HER2+ Breast Cancer with CNS Metastasis
Warrior, S., Cohen-Nowak, A. J., & Kumthekar, P. (2023) · Cancers · doi:10.3390/cancers15112908 · Cited by 14
“Tucatinib is a TKI that was studied in the HER2CLIMB randomized control trial in combination with capecitabine and trastuzumab that showed progression-free survival, overall survival, and improved CNS response rates [31].”
BackgroundShagisultanova, E. I., Gradishar, W. J., Brown-Glaberman, U. A., Chalasani, P., Brenner, A. J., Stopeck, A., Parris, H. J., Gao, D., McSpadden, T., Mayordomo, J. I., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0117 · Cited by 14
“%) is comparable with those reported in HER2CLIMB (6% – 8%; ref.”
InfluentialSelf-citationLi, Y., Tong, Z., Wu, X., Ouyang, Q., Cai, L., Li, W., Yu, Z., Han, Z., Wang, X., Li, M., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34676 · Cited by 14
“6 months with the addition of tucatinib to trastuzumab plus capecitabine.(31) In our study, patients with brain metastases at baseline could benefit from pyrotinib-based therapy, with a median rwPFS of 11.”
BackgroundKern, R., Corrêa, S., Scandolara, T. B., da Silva, J. C., Pires, B. R. B., & Panis, C. (2020) · Personalized Medicine · doi:10.2217/pme-2020-0070 · Cited by 15
Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
Tesch, H., Müller, V., Wöckel, A., Ettl, J., Belleville, E., Schütz, F., Hartkopf, A. D., Thill, M., Huober, J., Fasching, P. A., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1270-7481 · Cited by 13
Self-citationAguilar‐Mahecha, A., Lafleur, J., Brousse, S., Savichtcheva, O., Holden, K. A., Faulkner, N., McLennan, G., Jensen, T. J., & Basik, M. (2021) · Cancers · doi:10.3390/cancers13061331 · Cited by 14
“Indeed, the recent development of novel anti-HER2-targeted agents looks to significantly improve the prognosis of patients with this breast cancer subtype [5,6].”
BackgroundMatusz‐Fisher, A., & Tan, A. R. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1981284 · Cited by 16
“Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved this triplet combination in metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior anti–HER2-based regimens in the metastatic setting [11].”
BackgroundABC6 Consensus: Assessment by a Group of German Experts
Lüftner, D., Fasching, P. A., Haidinger, R., Harbeck, N., Jackisch, C., Müller, V., Schumacher-Wulf, E., Thomssen, C., Untch, M., & Würstlein, R. (2022) · Breast Care · doi:10.1159/000522068 · Cited by 13
Self-citationClinical Practice Guidelines for Brain Metastasis From Solid Tumors
Sung, K. S. (2024) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2023.0049 · Cited by 13
Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer
Kawakami, T., & Yamazaki, K. (2024) · Cancers · doi:10.3390/cancers16091747 · Cited by 12
“…therapy with tucatinib and trastuzumab plus capecitabine significantly prolonged PFS as the primary endpoint (HR: 0.54; 95% CI: 0.42–0.71; p < 0.001) in patients with HER2-positive metastatic breast cancer who had a history of anti-HER2 therapy compared with trastuzumab plus capecitabine [52].”
BackgroundInfluentialSun, K., Wang, X., Zhang, H., Lin, G., & Jiang, R. (2024) · Cancer Control · doi:10.1177/10732748241278039 · Cited by 16
“74,105 According to studies, tucatinib increases the risk of diarrhea and raises transaminase levels.”
BackgroundReal life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
Fabi, A., Rossi, A., Caputo, R., Pisegna, S., Scagnoli, S., Pantano, F., D’Auria, G., Fedele, P., Fabbri, A., Vernieri, C., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00801-3 · Cited by 17
“TheHER2CLIMBtrialpavedthewayforstudiesthatincludedpatients with active BMs 14 , demonstrating a clinically and statistically meaningful bene fi t with the addition of tucatinib, an anti-HER2 tyrosine kinase inhibitor, to trastuzumab and capecitabine: in patients with BMs, progression-free survival…”
Duan, F., Hua, X., Lu, W., Gui, X., Xie, J., Wang, X., Ma, Y., Zhai, W., & Xia, W. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02088-5 · Cited by 13
“…evidence further solidified T-DXd as a potent therapeutic option for patients with active brain involvement from HER2-positive and HER2-low MBC. Current, small-molecule HER2-targeting tyrosine kinase inhibitors (TKIs) as upfront systemic care of breast cancer BMs have been well established [20–23].”
InfluentialPredictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 17
Duvall, J. B., Massaad, E., Siraj, L., Kiapour, A., Connolly, I. D., Hadzipasic, M., Elsamadicy, A. A., Williamson, T. L., Shankar, G. M., Schoenfeld, A. J., et al. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002180 · Cited by 12
The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
Topletz‐Erickson, A. R., Lee, A. J., Mayor, J. G., Sun, H., Abdulrasool, L. I., Rustia, E. L., Walker, L. N., & Endres, C. J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01183-6 · Cited by 12
“This approval is based on results from the pivotal HER2CLIMB trial, in which tucatinib (300 mg twice daily) significantly prolonged progression-free survival (including in patients with brain metastases) and overall survival in patients who had previously received trastuzumab, pertuzumab, and trastuzumab emtansine [9,…”
BackgroundSelf-citationKatzendobler, S., Do, A., Weller, J., Rejeski, K., Dorostkar, M. M., Albert, N. L., Forbrig, R., Niyazi, M., Egensperger, R., Tonn, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1014711 · Cited by 18
“The evolving landscape of effective targeted therapies has significantly altered the management paradigm of BMs (7, 38, 39).”
BackgroundInfluentialIbragimova, K. I. E., Geurts, S. M. E., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., Pepels, M. J. A. E., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06832-9 · Cited by 12
“Until recently, international guidelines recommended that patients with HER2 + ABC are treated with first-line pertuzumab, trastuzumab plus taxane and with second-line T-DM1 regardless of hormone receptor (HR) status [8, 9].”
BackgroundGuan, X., Ma, F., Li, Q., Chen, S., Lan, B., Fan, Y., Wang, J., Luo, Y., Cai, R., Zhang, P., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00453-0 · Cited by 12
“In the HER2CLIMB trial [15] for heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, the median OS was 21.”
BackgroundPearson, J., Khan, A., Bhogal, T., Wong, H. H., Law, A., Mills, S. J., Santamaria, N., Bishop, J., Cliff, J., Errington, D., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102033 · Cited by 12
“6,7 It demonstrated an improvement in intracranial progression-free survival (PFS) from 4.2 to 9.9 months and a 42% reduction of risk of death [hazard ratio (HR) 0.58, 95% CI 0.40-0.85] for tucatinib in patients with BM. 7 The activity of the second-generation antibody drug conjugate (ADC)…”
BackgroundInfluentialUnlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
Bravo, M. J., Burgos-Molina, A. M., García‐Aranda, M., Redondo, M., & Téllez, T. (2023) · Cancers · doi:10.3390/cancers15235499 · Cited by 13
“This combination therapy can be employed to reduce the likelihood of disease progression or to enhance survival advantages in patients with HER2-positive metastatic breast cancer, regardless of the presence of brain metastases [134,135].”
BackgroundLimited brain metastases: a narrative review
Chaung, K. V., Sloan, A. E., & Choi, S. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-363 · Cited by 15
“For HER2-positive breast cancer, the combination of lapatinib and capecitabine has shown CNS activity (83-85), as has the combination of neratinib and capecitabine (86) and the combination of tucatinib, capecitabine, and trastuzumab (87,88).”
BackgroundCopur, M. S., Cushman‐Vokoun, A. M., Padussis, J. C., Wedel, W. R., Schroeder, C. W., Herold, D., Lintel, N. J., & Horn, A. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3506.0335 · Cited by 12
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Bartsch, R. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00722-4 · Cited by 12
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
Ni, J., & Zhang, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312820 · Cited by 12
Annonay, M., Gauquelin, L., Geiss, R., Ung, M., Cristol-Dalstein, L., Mouret‐Reynier, M., Gonçalvès, A., Abadie‐Lacourtoisie, S., François, É., Perrin, C., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.09.011 · Cited by 12
“Both lapatinib and T-DM1 contributed also to the global improvement of HER2þ MBC prognosis [6e8], and the list of anti-HER2 treatments has been updated very recently with tucatinib and new antibody-drug conjugates as DS-8201 [9,10].”
BackgroundVeitch, Z. W. N., Ribnikar, D., Tilley, D. G., Tang, P. A., King, K. M., Bedard, P. L., Lupichuk, S., & Cescon, D. W. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01676-4 · Cited by 13
“Although the majority of patients eventually progress and succumb to their disease, a minority of MBC patients experience a complete response (~1–6%) [4, 6, 8] or no evidence of disease (NED), with long-term survival to HER2targeted therapies [9, 10].”
BackgroundInfluentialSelf-citationTargeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies
Chiec, L. S., & Kumthekar, P. (2022) · CNS Drugs · doi:10.1007/s40263-021-00894-x · Cited by 13
“Subsequently, the HER2CLIMB trial evaluated this combination in an international, randomized, double-blind study in comparison with placebo plus trastuzumab and capecitabine [39].”
MethodImmunological Landscape of HER-2 Positive Breast Cancer
Moragón, S., Hernándo, C., Martinez-Martinez, M. T., Tapia, M., Ortega-Morillo, B., Lluch, A. M., Bermejo, B., & Cejalvo, J. M. (2022) · Cancers · doi:10.3390/cancers14133167 · Cited by 14
Multidisciplinary Management of Brain Metastasis from Breast Cancer
Trapani, D., Aizer, A. A., & Lin, N. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.017 · Cited by 12
Self-citationEvaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Baroz, A. R., Chao, J., Chen, C., Nasser, M. W., Chirravuri‐Venkata, R., Jain, M., et al. (2021) · Cancers · doi:10.3390/cancers13112776 · Cited by 14
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Lim, M., Fletcher, N. L., Reed, A. E. M., Flint, M., Thurecht, K. J., Saunus, J. M., & Lakhani, S. R. (2022) · Journal of Visualized Experiments · doi:10.3791/64216 · Cited by 11
Shan, W., Shen, C., Luo, L., & Ding, P. (2023) · iScience · doi:10.1016/j.isci.2023.108020 · Cited by 11
Giordano, G., Griguolo, G., Landriscina, M., Meattini, I., Carbone, F., Leone, A., Re, M. D., Fogli, S., Danesi, R., Colamaria, A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104185 · Cited by 14
Jin, N., Xu, Y., Wang, S., Sun, C., Yan, X., Yang, F., Liang, Y., Chen, W., & Huang, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.10.004 · Cited by 11
“11 Inetetamab is a recombinant humanized anti-HER2 monoclonal antibody that has the same Fab segment as trastuzumab, while modi fi es Fc segment to endow greater antibody-dependent cell-mediated cytotoxicity (ADCC) than trastuzumab.”
BackgroundMetastatic Breast Cancer: Prolonging Life in Routine Oncology Care
Weide, R., Feiten, S., Wassmann, C., Rendenbach, B., Braun, U., Burkhard, O., Ehscheidt, P., & Schmidt, M. (2024) · Cancers · doi:10.3390/cancers16071255 · Cited by 14
“…the therapeutic options for HER2-positive MBC. Tucatinib in combination with capecitabine + trastuzumab proved superior to the combination of capecitabine + trastuzumab in the third or more line after trastuzumab, pertuzumab and trastuzumab–emtansine anti HER2-therapy in the HER2-CLIMB study [25].”
BackgroundHuppert, L. A., Fisch, S. C., Tsopurashvili, E., Somepalle, S. S., Salans, M. A., Vasudevan, H. N., Chien, A. J., Majure, M. C., Rugo, H. S., Balassanian, R., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07339-1 · Cited by 11
“Improvements and advances in HER2 targeted TKIs including neratinib, tucatinib, and pyrotinib have improved outcomes for patients with HER2 + MBC with CNS disease [23–25].”
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer
Müller, V., Bachelot, T., Curigliano, G., de Azambuja, E., Furtner, J., Gempt, J., Jereczek‐Fossa, B. A., Jerzak, K. J., Rhun, É. L., Palmieri, C., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102860 · Cited by 14
Self-citationGiannoudis, A., Sokol, E. S., Bhogal, T., Ramkissoon, S. H., Razis, E. D., Bartsch, R., Shaw, J., McGregor, K., Clark, A., Huang, R. S. P., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00761-0 · Cited by 15
Zhang, X., Yin, Y., Yu, Q., Chen, X., & Cheng, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1492203 · Cited by 14
Wang, X., Lee, K. S., Zeng, X., Sun, T., Im, Y., Li, H., Wang, K., Zhou, P., Li, V., Chen, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105852 · Cited by 11
Targeted Therapies for Each Subtype of Breast Cancer
Liu, A., Peng, P., Zhu, Y., Fei, Q., Liu, W., & Zhang, S. (2026) · MedComm · doi:10.1002/mco2.70733 · Cited by 15
Advances in Management of Brain and Leptomeningeal Metastases
Venur, V. A., Chukwueke, U. N., & Lee, E. Q. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01039-1 · Cited by 11
Advances in EGFR/HER2-directed clinical research on breast cancer
Chow, L. W., Lie, E. F., & Toi, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.009 · Cited by 11
Kostos, L. K., Hong, W., Lee, B., Tran, B., Lok, S. W., Anton, A., Gard, G., To, Y. H., Wong, V., Shapiro, J. D., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33568 · Cited by 12
“The management of HER2-amplified metastatic BC also continues to evolve.(34) Any improvement in outcomes over time as we report needs to be factored into the statistical plan for future studies where the intervention arm of a prior positive study becomes the control arm for the next study.”
BackgroundThe management of HER2‐positive early breast cancer: Current and future therapies
Chen, J., Colosimo, M. L., & Lim, E. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13655 · Cited by 12
Wang, Y., Xu, H., Han, Y., Wu, Y., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14143372 · Cited by 11
“Particularly, the HER2CLIMB trial also included patients with active (progressive and/or untreated) BCBM [27].”
BackgroundCurrent Frontline Treatment of Multiple Myeloma
Holstein, S. A. (2022) · ONCOLOGY · doi:10.46883/2022.25920967 · Cited by 13
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
Li, J., Wang, X., Wang, S., Wang, S., Wang, T., Liu, Y., Geng, C., Jin, F., Yin, Y., Zhang, Q., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-48 · Cited by 13
“The HER2CLIMB study (27), showed that tucatinib combined with trastuzumab plus capecitabine significantly prolonged PFS and OS; in particular, it significantly reduced the risk of disease progression or death in patients with brain metastases.”
Xu, L., Han, F., Zhu, L. W., Ding, W., Zhang, K., Kan, C., Hou, N., Li, Q., & Sun, X. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5496 · Cited by 13
“A phase III trial indicated that tucatinib plus capecitabine and trastuzumab significantly prolonged progression-free survival and overall survival in patients with HER2-positive BC (33).”
BackgroundLiu, B., Xie, N., Tian, C., Feng, R., Hu, Z.-Y., Li, J., Liu, L., Xiao, H., Yang, X. R., Zeng, M., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.103597 · Cited by 12
“The HER2CLIMB study [22] demonstrated that adding tuca-tinib to trastuzumab and capecitabine improved PFS and OS in advanced breast cancer patients.”
BackgroundEvaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents
Josefsson, A., Cortez, A. G., Yu, J., Majumdar, S., Bhise, A., Hobbs, R. F., & Nedrow, J. R. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108880 · Cited by 12
Al-Ghamdi, A. R., Ahmed, W. U., Al-Wabli, R. I., Almutairi, M. S., & Rahman, A. F. M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020833 · Cited by 12
Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era
Cherri, S., Noventa, S., Fanelli, M., Calandra, G., Prochilo, T., Bnà, C., Savelli, G., & Zaniboni, A. (2021) · Cancers · doi:10.3390/cancers13051052 · Cited by 12
“Tucatinib [53] HER2-positive advanced BC (+Capecitabine + Trastuzumab) 1.”
BackgroundTeyateeti, A., Brown, P. D., Mahajan, A., Laack, N. N., & Pollock, B. E. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab036 · Cited by 11
Pizzuti, L., Krasniqi, E., Sperduti, I., Barba, M., Gamucci, T., Mauri, M., Veltri, E. M., Meattini, I., Berardi, R., Lisa, F. S. D., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059873 · Cited by 11
Mastering the Use of Novel Anti-HER2 Treatment Options
Tarantino, P., Trapani, D., & Curigliano, G. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00216 · Cited by 12
Self-citationMiglietta, F., Pontolillo, L., Angelis, C. D., Caputo, R., Mariño, M., Bria, E., Rienzo, R. D., Verrazzo, A., Buonerba, C., Tortora, G., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103713 · Cited by 10
Ding, N., Hermans, K. E. P. E., van Nijnatten, T. J. A., Engelen, S. M. E., Tol, J., Kooreman, L. F. S., Peeters, M.-J. T. F. D. V., Siesling, S., Voogd, A. C., Tjan‐Heijnen, V. C. G., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115475 · Cited by 11
Genomic and immune profiling of breast cancer brain metastases
Swearingen, A. E. D. V., Lee, M. R., Rogers, L. W., Sibley, A. B., Shi, P., Qin, X., Goodin, M., Seale, K. N., Owzar, K., & Anders, C. K. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02001-3 · Cited by 11
“…inhibitors, notably tucatinib-based regimens, enrichment of HER2, and the ability of both immunohistochemical and molecular subtyping methods to accurately identify these cases in patients with BCBrM will alter the therapeutic approach and potential outcomes for these patients [10, 33, 58, 68].”
Self-citationCorti, C., Rugo, H. S., & Tolaney, S. M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-100053 · Cited by 13
DeBusk, K. P. A., Abeysinghe, S., Vickers, A. D., Nangia, A., Bell, J. A., Ike, C., Forero, A., & Blahna, M. T. (2021) · Future Oncology · doi:10.2217/fon-2021-0742 · Cited by 12
The Most Recent Discoveries in Heterocyclic Nanoformulations for Targeted Anticancer Therapy
Bhattacharya, S., Patel, R., & Joshi, A. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955752203220202164839 · Cited by 12
Advances in the Management of Central Nervous System Metastases from Breast Cancer
Ávila, J., & Leone, J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012525 · Cited by 10
Gligorov, J., Benderra, M., Barthere, X., Forceville, L. D., Antoine, É.-C., Cottu, P. H., Delaloge, S., Pierga, J., Belkacémi, Y., Houvenaegel, G., et al. (2023) · Bulletin du Cancer · doi:10.1016/s0007-4551(23)00473-3 · Cited by 11
Self-citationXiong, W., Xu, T., Liu, X., Zhang, L., & Yuan, Y. (2024) · Cancer · doi:10.1002/cncr.35206 · Cited by 10
“13 Meanwhile, the result was comparable with the TH3RESA trial (T ‐ DM1, 6.20 months) and the NALA trial (neratinib plus capecitabine, 8.80 months) in patients with progressive disease after two or more anti ‐ HER2 ‐ targeted regimens.”
ResultInfluentialÁvila, J., Leone, J., Vallejo, C. T., Lin, N., & Leone, J. P. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07290-1 · Cited by 10
“…of patients with metastatic HER2-positive breast cancer has improved in recent years with the development of tucatinib and trastuzumab deruxtecan [ 29, 30], both of which have been shown to confer an overall survival benefit in randomized trials, and are not well represented in our cohort given…”
Self-citationSynthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy
Liu, H., Zhu, Y., Chi, Y., Zhang, Y., Li, X., Wen, W., Shan, L., Wang, Y., & Dai, B. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107653 · Cited by 12
Zheng, S., Chen, R., Zhang, L., Tan, L., Li, L., Long, F., & Wang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116702 · Cited by 11
Niu, L., Lv, H., Zhang, M., Zeng, H., Wang, L., Cui, S., Liu, Z., & Yan, M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3734 · Cited by 10
“This may be attributable to the continued clinical application of increasingly efficacious anti-HER2 treatment regimens in recent years (33-36,40).”
BackgroundManagement of complications from brain metastasis treatment: a narrative review
Diao, K., Sosa, A., Zada, G., Nagpal, S., & Chang, E. L. (2022) · Chinese Clinical Oncology · doi:10.21037/cco-21-90 · Cited by 11
“Two randomized controlled trials have found better neurocognitive preservation with SRS alone compared to SRS with WBRT with similar OS in patients with limited (1-3) brain metastases (8,9).”
BackgroundInfluentialCutaneous toxicity of FDA-approved small-molecule kinase inhibitors
Du, J., Yan, H., Xu, Z., Yang, B., He, Q., Wang, X., & Luo, P. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2004116 · Cited by 10
Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles
Steindl, A., Brastianos, P. K., Preusser, M., & Berghoff, A. S. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab105 · Cited by 12
Hua, Y., Li, W., Jin, N., Cai, D., Sun, J., Sun, C., Yang, F., Wu, X., Huang, X., Wang, B., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221085232 · Cited by 11
Tuly, K. F., Hossen, M. B., Islam, M. A., Kibria, M. K., Alam, M. S., Harun-Or-Roshid, M., Begum, A., Hasan, S., Mahumud, R. A., & Mollah, M. N. H. (2023) · Medicina · doi:10.3390/medicina59101705 · Cited by 11
Fan, K. Y., Lalani, N., LeVasseur, N., Krauze, A. V., Hsu, F., Gondara, L., Willemsma, K., & Nichol, A. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03657-8 · Cited by 10
“Targeted therapies, such as EGFR and ALK in non-small cell lung cancer [9], HER2 in breast cancer [10] and BRAF in melanoma are highly effective [11].”
BackgroundJackisch, C., Barcenas, C. H., Bartsch, R., Palma, J. D., Glück, S., Harbeck, N., Macedo, G., O’Shaughnessy, J., Pistilli, B., Ruíz‐Borrego, M., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.02.001 · Cited by 10
Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis
Xiong, S., Tan, X., Wu, X., Wan, A., Zhang, G., Wang, C., Liang, Y., & Zhang, Y. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231165976 · Cited by 9
Gogineni, E., Sells, B. E., Dibs, K. N., Jhawar, S. R., Haring, C. T., Limbach, A. L., Konieczkowski, D. J., Ma, S. J., Zhu, S., Baliga, S., et al. (2024) · Cancers · doi:10.3390/cancers16061204 · Cited by 9
Karihtala, P., Schiza, A., Fountzilas, E., Geisler, J., Meattini, I., Risi, E., Biganzoli, L., & Valchis, A. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2023.40365 · Cited by 10
Manna, M., Gelmon, K. A., Boileau, J.-F., Brezden‐Masley, C., Cao, J. Q., Jerzak, K. J., Prakash, I., Sehdev, S. R., Simmons, C. E., Bouganim, N., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110484 · Cited by 9
Self-citationA Site-Specific MiniAp4–Trastuzumab Conjugate Prevents Brain Metastasis
Masmudi‐Martín, M., Oller‐Salvia, B., Perea, M., Teixidò, M., Valiente, M., Giralt, E., & Sánchez‐Navarro, M. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01091 · Cited by 9
New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies
LeVee, A. A., Deutsh, A., Lindgren, E. S., Yan, R., Moore, H., Pasricha, N. D., Leventhal, J. S., Dent, S. F., & Rugo, H. S. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473384 · Cited by 11
Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition)
Breast Cancer Expert Committee of the National Quality Control Center for Cancer, Breast Cancer Expert Committee of the China Anti-Cancer Association, & Cancer Drug Clinical Research Committee of the China Anti-Cancer Association (2025) · Cancer Innovation · doi:10.1002/cai2.70032 · Cited by 11
Ma, F., Yan, M., Li, W., Ouyang, Q., Tong, Z., Teng, Y., Wang, Y., Wang, S., Geng, C., Luo, T., et al. (2026) · BMJ · doi:10.1136/bmj-2025-087259 · Cited by 13
Hashimoto, Y., Hayashi, A., Teng, L., & Igarashi, A. (2021) · Journal of Palliative Medicine · doi:10.1089/jpm.2020.0649 · Cited by 9
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer
Ahn, D. H., Walden, D. M., & Bekaii‐Saab, T. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2053107 · Cited by 9
Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
Müller, V., Welslau, M., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1811-6148 · Cited by 9
“▶ Table 1 Original texts for the inclusion and exclusion criteria related to brain metastases in the DESTINY‐B03 and HER2CLIMB trials (according to [46] and [47]).”
Self-citation
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.